T. Rowe Price Associates’s Pharvaris PHVS Stock Holding History

T. Rowe Price Associates’s Portfolio PHVS Stock Details PHVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$12.5M	Sell	442,256 -499,349	-53%	-$13.3M	﹤0.01%	1163
2025 Q4	$26.1M	Buy	941,605 +124,797	+15%	+$3.01M	﹤0.01%	1002
2025 Q3	$20.4M	Buy	816,808 +49,493	+6%	+$1.1M	﹤0.01%	1055
2025 Q2	$13.5M	Buy	767,315 +181,228	+31%	+$2.92M	﹤0.01%	1057
2025 Q1	$9.2M	Buy	586,087 +142,191	+32%	+$2.4M	﹤0.01%	1129
2024 Q4	$8.51M	Buy	443,896 +118,408	+36%	+$2.44M	﹤0.01%	1178
2024 Q3	$6.03M	Sell	325,488 -259,783	-44%	-$4.75M	﹤0.01%	1242
2024 Q2	$11M	Sell	585,271 -172,644	-23%	-$3.51M	﹤0.01%	1094
2024 Q1	$17.5M	Sell	757,915 -84,783	-10%	-$2.25M	﹤0.01%	1005
2023 Q4	$23.6M	Buy	+842,698	New	+$17.1M	﹤0.01%	916

Other funds holding PHVS

General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

FCMI

Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return

venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

EFM

EQT Fund Management Luxembourg $1.02B AUM

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

T. Rowe Price Associates's PHVS Position: Q1 2026 in Review

T. Rowe Price Associates reduced its Pharvaris (PHVS) stake by 53% in Q1 2026, selling an estimated $13.3M and leaving 442,256 shares worth $12.5M. The position accounts for ﹤0.01% of the portfolio, ranked #1163.

T. Rowe Price Associates first reported a position in PHVS in Q4 2023 and has held it in 10 quarters since. The position peaked at $26.1M in Q4 2025. 110 funds tracked by Wall St. Rank hold PHVS as of Q1 2026.

T. Rowe Price Associates held 442,256 shares of Pharvaris worth $12.5M as of Q1 2026.
T. Rowe Price Associates sold 499,349 Pharvaris shares in Q1 2026, an estimated $13.3M.
Pharvaris made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q1 2026, its #1163 holding.
T. Rowe Price Associates first reported a position in Pharvaris in Q4 2023 and has held it in 10 quarters since.
T. Rowe Price Associates's Pharvaris position peaked at $26.1M in Q4 2025.
110 funds tracked by Wall St. Rank held Pharvaris as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.